- Home
- ACON vs ZVSA Comparison
ACON vs ZVSA Comparison
Compare ACON & ZVSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACON
- ZVSA
- Stock Information
- Founded
- ACON 2008
- ZVSA 2014
- Country
- ACON United States
- ZVSA United States
- Employees
- ACON N/A
- ZVSA N/A
- Industry
- ACON Retail: Computer Software & Peripheral Equipment
- ZVSA Biotechnology: Pharmaceutical Preparations
- Sector
- ACON Technology
- ZVSA Health Care
- Exchange
- ACON Nasdaq
- ZVSA Nasdaq
- Market Cap
- ACON 7.1M
- ZVSA 3.5M
- IPO Year
- ACON 2022
- ZVSA N/A
- Fundamental
- Price
- ACON $12.61
- ZVSA $0.59
- Analyst Decision
- ACON Buy
- ZVSA Strong Buy
- Analyst Count
- ACON 2
- ZVSA 1
- Target Price
- ACON $481.00
- ZVSA $240.00
- AVG Volume (30 Days)
- ACON 370.3K
- ZVSA 125.6K
- Earning Date
- ACON 05-14-2025
- ZVSA 05-14-2025
- Dividend Yield
- ACON N/A
- ZVSA N/A
- EPS Growth
- ACON N/A
- ZVSA N/A
- EPS
- ACON N/A
- ZVSA N/A
- Revenue
- ACON $49,289.00
- ZVSA N/A
- Revenue This Year
- ACON N/A
- ZVSA N/A
- Revenue Next Year
- ACON $186.36
- ZVSA N/A
- P/E Ratio
- ACON N/A
- ZVSA N/A
- Revenue Growth
- ACON N/A
- ZVSA N/A
- 52 Week Low
- ACON $9.75
- ZVSA $0.58
- 52 Week High
- ACON $6,241.05
- ZVSA $8.05
- Technical
- Relative Strength Index (RSI)
- ACON 33.96
- ZVSA 27.23
- Support Level
- ACON $9.75
- ZVSA $0.69
- Resistance Level
- ACON $15.08
- ZVSA $0.65
- Average True Range (ATR)
- ACON 3.14
- ZVSA 0.06
- MACD
- ACON 12.50
- ZVSA -0.00
- Stochastic Oscillator
- ACON 13.43
- ZVSA 3.04
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The Company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.